We are very honoured to count MSD among the Sponsors of BioFIT 2020

Many thanks to MSD for joining BioFIT 2020 as a Silver Sponsor

MSD is an innovative, global healthcare leader that is committed to improving health and well-being around the world. Its core product categories include diabetes, cancer, vaccines and hospital acute care. They continue to focus their research on conditions that represent some of today’s most significant health challenges – like cancer, HIV, HPV, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer’s disease, and they are on the front lines in the fight against emerging global pandemics, such as ebola. They also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver their products to the people who need them. At MSD, They’re applying their global reach, financial strength and scientific excellence to do more of what they’re passionate about: improving health and improving lives.

Join key BioFIT 2020 sponsors such as MSD Animal Health, Evotec and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

ALCEDIAG, elected as the most promising technology of BioFIT 2019

35 TTOs, universities, research institutes and companies applied to the Collaborative and Licensing Opportunity Presentations to showcase their technology in front of potential partners in order to entail a collaborative project and / or a licensing deal. 9 of them have been selected to pitch during BioFIT in 4 different categories: diagnostic, CNS, cell-therapy and infection. ALCEDIAG, represented by Marianne Morini, Business Development Manager, received the “Most promising Technology” award.

Please introduce yourself and ALCEDIAG. How your company is born?

Marianne Morini: ALCEDIAG is a precision diagnostics company developing blood-based diagnostic solutions based on epigenetics biomarkers (RNA editing) and artificial intelligence. The company has a first focus on mental health. The tests and software that we develop help to characterize the psychiatric patient, from the initial diagnosis to the monitoring of the disease and the assessment of the response to treatment.

Our first product EDIT-B® will obtain CE mark in 2020. It is a blood test to differentiate patients with bipolar disorder from patients from unipolar depression. Today, this differentiation is particularly complicated to perform with existing clinical tools. It is one of the key reasons explaining why bipolar disorder requires in average 7,5 years to be diagnosed. With EDIT-B, which is biological, rapid and highly accurate, we believe we can significantly reduce diagnostic wandering and help millions of patients in the world.

ALCEDIAG was born in 2013 from the combined visions of Dinah Weissmann, our CSO, and ALCEN, the mother company of ALCEDIAG. Dinah had an extensive experience in RNA editing and a deep understanding of what epigenetics would bring to the world of psychiatry. ALCEN is a family owned group who invests in breakthrough technologies with the ambition to bring to the market solutions for some of today’s key issues. Together, they decided to tackle the issue of biological diagnosis for mental health.

Why did you apply to the Collaborative and Licensing Opportunity Presentations? What was your expectations?

M. M.: Our goal is to partner with leading life science companies (pharma and diagnostic industry) to make our tests accessible to a large number of patients. When applying for the Collaborative and Licensing Opportunity Presentations, we knew that many of these life science companies attending Biofit would be likely to hear about our innovative technologies and products. It was an opportunity for us to increase our visibility and our chances of finding a valuable partner.

What did this victory as the Most Promising Technology bring to you and your company?

M. M.: We are proud of this award of the Most Promising Technology. First, it is a confirmation that our products are appealing to the pharma industry and to investors who were on the jury, and that we are on the right way in terms of development. As a team, it is also a recognition of our work and of our accomplishments. Then, it definitely increased our visibility during BIOFIT, attracted many people to our stand and allowed us to connect with a lot potential partners. After a few weeks, we can see that these benefits last beyond the congress thank to the media coverage and the contacts we made at the congress.

What’s next for ALCEDIAG now?

M. M.: The next major milestone for us is the CE marking of our first diagnostic test which is expected in a few months. The market opportunity is huge as depression – and personalized diagnosis of different types of depression – is a major medical concern in all countries. And psychiatry is a wide field that definitely needs biology to progress towards precision medicine and we keep on working hard to develop other useful solutions to unmet needs.

ALCEDIAG is a precision diagnostics company with a first focus on mental health. The company develops blood-based diagnostic solutions for psychiatric diseases based on proprietary biomarkers. In addition, the company has developed a biomarker discovery platform that can be used for different types of pathologies (neuropsychiatry, inflammatory diseases, cancer) as well as cell tests allowing the modeling of the impact of drugs on patients and more precisely the potential psychiatric adverse side effects induced by drugs.

More information: www.alcediag-alcen.com

Discover the BioFIT 2020 brand new brochure!!

In this brochure, you will find all the information you need about the 9th edition of the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

MediSieve Ltd., elected as the most innovative start-up

Among 50 applications, 19 start-ups were selected to pitch during the Start-up Slams at BioFIT in different categories such as cell-therapy, cardio-metabolic, wound-care, animal health, cancer and CNS. MediSieve Ltd., an English start-up represented by George Frodsham, founder and CEO, is the winner of this year’s edition of the Start-up Slams, from the cancer category.

We were very pleased to be one of the winners of the pitching contest at BioFIT. These pitching sessions are really valuable opportunities to showcase MediSieve to an audience of potential partners and investors, to share with them the work we’re doing and progress that we’ve made. Winning the award of “most innovative start-up” in a highly competitive line-up, was great further recognition of our work.” George Frodsham – Founder and CEO

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood borne diseases. The company’s initial targets include Sepsis, Leukaemia and Malaria. Located in the new Imperial College Translation and Innovation Hub in White City, the company is preparing for first in man trials in 2019.

ALCEDIAG, elected as the most promising technology

35 TTOs, universities, research institutes and companies applied to the Collaborative and Licensing Opportunity Presentations to showcase their technology in front of potential partners in order to entail a collaborative project and / or a licensing deal. 9 of them have been selected to pitch during BioFIT in 4 different categories: diagnostic, CNS, cell-therapy and infection. ALCEDIAG, represented by Marianne Morini, Business Development Manager, received the “Most promising Technology” award

We are very proud to win this award! It means that our achievements in developing accurate blood tests for precision psychiatry are appealing not only to clinicians and patients but also to pharma companies and investors who were in the jury. We are convinced that this award will contribute to improve our visibility and to gain additional market traction in the coming weeks…” Marianne Morini, Business Development Manager

ALCEDIAG is a precision diagnostics company with a first focus on mental health. The company develops blood-based diagnostic solutions for psychiatric diseases based on proprietary biomarkers. In addition, the company has developed a biomarker discovery platform that can be used for different types of pathologies (neuropsychiatry, inflammatory diseases, cancer) as well as cell tests allowing the modeling of the impact of drugs on patients and more precisely the potential psychiatric adverse side effects induced by drugs.

Velabs Therapeutics GmbH, elected as the most innovative offer

11 innovative offers have been selected among service providers and technology platforms that applied to the Service Presentations. They showcased their offer in front of potential clients. Velabs Therapeutics, represented by Dr. Christoph Antz, Managing Director, received the “Most innovative offer” award.

I was attending the Pitch session in order to (a) leverage our company’s visibility, (b) to have an external and independent view on it by experts and (c) to increase our chances finding potentially interested collaboration partners during BioFIT, which, after all, is morphing more and more to a bigger European high quality meeting, comparable to BioEurope and other formats. I did not do it for winning the price, for sure. The announcement of Velabs as a winner really surprised me, as I felt the level of competition extremely high, having heard all the other top pitches. So last not least, I am happy about the price and very proud, that we could do it! We feel honored by the jury’s decision and hope to fulfill the expectations in the field, which is full of good concepts and strong competitors, even in our narrow field of microfluidic screening. We consider the jury’s vote as a validation of our concept and technology.” Dr. Christoph Antz, Managing Director

Velabs is a leading pioneer in microfluidics-based technologies for functional screening of antibodies. Our high-throughput screening platform allows for testing millions of correctly paired fully natural IgGs from humans and mice for therapeutic effects, rather than just for binding. Rare functional hits are readily  identified, which might be laborious or even impossible using other technologies. Velabs’ antibody screens can thus significantly and competitively shorten pre-clinical development.

AND BioPharma, elected as the most innovative animal health project

3 innovative animal health projects have been selected among companies that applied to the Animal Health Collaborative Opportunity Presentations and showcased their project in front of potential partners and investors. AND BioPharma, a Belgium project represented by Peter Jens, CEO and Business Development, is the winner of this year’s edition of the Animal Health Collaborative Opportunity Presentations.

AND BioPharma was present last year in BioFIT Lille and we were surprised about the gigantic partnering effort that was organised. As we originate from agriculture we are not used to “everybody doing it with everybody”. Yet we think it is the way forward. Diversity in partnerships will deliver the greatest value to farmers, patients and citizens alike. Hence, we opted to pitch our intriguing, disruptive and remarkable DNA selftoxicity technology in Marseille and, lo and behold, we won an award for “most innovative animal health project”. Of course, the project is really about improving mammalian health, but the industry still makes a difference between animals and humans. We look forward to be present at BioFIT 2020 in Strasbourg….” Peter Jens, CEO and Business Development

AND Biopharma stimulates, in collaboration with the pharmaceutical industry, healthcare providers, insurance companies and thoughtleaders, the natural balance between hosts and troublesome invaders in humans and other animals. By the development of efficient and effectual medicines based on the powerful and proven self DNA-inhibition principle, discovered and patented at Frederico II University, Napels, Italy.

Marseille – December 10th & 11th 2019

ON[e]Life

ON[e]Life is a multi-expertise platform that aims to accelerate the development of biotechnology and e-health companies and to create bridges between life sciences and digital technologies. ON[e]Life is a driving-ecosystem actor focusing on worldwide digital transformation of life sciences, medicine, health and spread it through international collaborations.

 

Hackathon

A Hackathon is a multi-day event where a team of creators / innovators (developers, doctor, students, clinicians, etc.) works together on a disruptive project using collaborative computer programming. This creative process is frequently used in the field of digital innovation (Briscoe & Mulligan, London’s Digital Economy, 2014). For the last two years, we have applied this process towards life sciences, medicine and health and we wish to replicate it.

 

The project

Organized for the third time this Hackathon is dedicated to facilitate bridges between artificial intelligence and life sciences, medicine and health. ON[e]Life’s aims to promote and engage R&D collaborations between these two worlds to accelerate the translational research phase and the go-to-market of disruptive products (access to patients).

 

Format

On the day of the event, a 24-hour countdown will be launched. Teams will work on their projects with help of mentors on site. After these 24 hours, participants will pitch their projects for 3-5 minute in front of the jury. Each team will produce an innovative project that will be evaluated by a jury of professionals according to well-defined criteria.

HACKATHON 2019 – PROGRAMME

Hack your senses : Transform one sense to another for better Health and Well-Being

December 10th  2019 – Hackathon

9.00 am- 12.00 pm – Setting & Bootcamp with all participants

 2.00 pm- 8.00 pm – Technical Mentoring (IA, biosensors, biology, physicians)

 

December 10th 2019 – Symposium

6.00 pm- 7.00 pm – Data Security, Sharing & Innovation

Pascal STACCINI – CHU Nice

7.00 pm – 8.00 pm – Cybernetic or Biological Enhancement towards Human Immortality

Pierre Grand-Dufay

Olivier Oullier

Miroslav Radman

 

 December 11th , 2019 – Hackathon

9.00 am- 12.00 pm – Business & Marketing Mentoring Marketing

1.30 pm- 3.30 pm –Hacakthon Project Pitches

3.30 pm- 4.00 pm – Jury Deliberation

4.00 pm- 4.30 pm – Award Ceremony

4.30 pm- 5.00 pm – Conclusion & Networking

Many thanks to Alzprotect for joining BioFIT 2019 as a Contributing Sponsor

AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, Pfizer, Innate Pharma, Genfit, Roche, Advent France Biotechnology, LFB, ONTOFORCE, IPSEN, MSD Animal Health, Alzprotect and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Many thanks to Roche for joining BioFIT 2019 as a Bronze Sponsor

As a pioneer in healthcareRoche has been committed to improving lives since the company was founded in 1896. Today, Roche creates innovative medicines and diagnostics tests for millions of patients.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, Pfizer, Innate Pharma, Genfit, Roche, Advent France Biotechnology, LFB, ONTOFORCE, IPSEN, MSD Animal Health and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Many thanks to Innate Pharma for joining BioFIT 2019 as a Contributing Sponsor

Innate Pharma is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer..

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, Pfizer, Innate Pharma, Genfit, Advent France Biotechnology, LFB, ONTOFORCE, IPSEN, MSD Animal Health and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Many thanks to Genfit for joining BioFIT 2019 as a Silver Sponsor

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical need.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, Pfizer, Genfit, Advent France Biotechnology, LFB, ONTOFORCE, IPSEN, MSD Animal Health and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Many thanks to IPSEN for joining BioFIT 2019 as a Bronze Sponsor

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. Their goal is to leave no patient behind and their mission is to prolong and improve patients’ lives and health outcomes, through launching at least one new molecular entity or meaningful indication each year.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, Pfizer, Advent France Biotechnology, LFB, ONTOFORCE, IPSEN, MSD Animal Health and MSD to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.